Groups | Latent TB cases (n=45) | Non-TB controls (n=40) | ||||||
Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | |
All TB cases | ||||||||
HIV negative | 86 | 80 | 89 | 86 | 86 | 94 | 98 | 74 |
HIV positive | 90 | 80 | 94 | 73 | 91 | 94 | 96 | 90 |
Pulmonary TB | ||||||||
HIV negative | 80 | 80 | 79 | 88 | 80 | 94 | 95 | 81 |
HIV positive | 86 | 80 | 85 | 89 | 90 | 94 | 92 | 94 |
Pleural TB | ||||||||
HIV negative | 80 | 80 | 75 | 97 | 87 | 94 | 94 | 94 |
HIV positive | 86 | 80 | 67 | 89 | 80 | 91 | 80 | 94 |
Lymph node TB | ||||||||
HIV negative | 86 | 80 | 77 | 97 | 84 | 94 | 94 | 94 |
HIV positive | 100 | 78 | 80 | 100 | 100 | 91 | 88 | 94 |
↵* Patients with active TB were compared with latent TB cases or non-TB controls.
ALS, Antibodies in Lymphocyte Supernatant; NPV, negative predictive value; PPV, positive predictive value; TB, tuberculosis.